Search Results 171-180 of 7941 for TNF

1. A Study to Evaluate CC-98633 to Treat Subjects with Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   ... TNF, anti-IL6, or anti-IL6R) or in need of such therapies;; Donor lymphocyte infusions within 6 weeks before leukapheresis;; Radiation to a single lesion or a ...

2. A Study to Evaluate the Effectiveness and Safety of Obeticholic Acid to Treat Patients with Primary Sclerosing Cholangitis - Mayo Clinic

   Subjects being administered biologic treatments (eg, anti-tumor necrosis factor (TNF) or anti-integrin monoclonal antibodies), immunosuppressants, systemic ...

3. Neurology - Clinical trials - Mayo Clinic

   Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...

4. A Study to Evaluate the Safety, Effectiveness and Microbiological Response of Orally Administered ABI-M201 in Subjects with Mildly-to-Moderately Active Ulcerative Colitis with Ongoing Mesalamine Treatment - Mayo Clinic

   ... TNF-alpha-antagonists, anti-integrin therapies, agents targeting IL-12 or IL-23, etc.). Known intolerance/allergic reaction to imipenem or metronidazole ...

5. Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis - Mayo Clinic

   * Belimumab, telitacicept, abatacept, TNF-? mAb, immunoglobulins (i.v./s.c.) plasmapheresis * Any other immuno-suppressants (i.v. or oral cyclophosphamide ...

6. COVID-19 Tests Clinical Trials - Mayo Clinic Research

   Hypothesis: Baseline cytokine (IL-1β, IL-6, IL-4, IL-10, IFN-g and TNF-a) and the immune cellular repertoire (helper/CD4+, cytotoxic/CD8+, T-regulatory ...

7. A Study of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease - Mayo Clinic

   ... TNF-α antagonist or vedolizumab or ustekinumab, or having documented intolerance. Women of childbearing potential (WCBP) must have negative serum pregnancy ...

8. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   anti-TNF alpha agents) =< 2 weeks prior to randomization, or anticipation of need for systemic immunosuppressive medication during study treatment, with the ...

9. A Study to Evaluate CPI-006 with Standard of Care vs. Placebo with Standard of Care in Mild-to-moderately Symptomatic Hospitalized Covid-19 Patients (Enrolling by Invitation Only) - Mayo Clinic

   Receipt of cancer chemotherapy or immunomodulatory drugs including (but not limited to) biologics such as anti-CD20, anti-TNF, anti-IL6; alkylating agents ...

10. A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease (UNITI-2) - Mayo Clinic

    ... TNF-antagonist therapies (ie, infliximab, adalimumab, or certolizumab pegol) per study criteria; Have screening laboratory test results within protocol ...